After a conference lacking the wow factor, biotech winners and losers emerge.

Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.

Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.

What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.

Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.

If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.